BELLUS Health Inc.

0A4U - LSE
Save to watchlist

Add to calculator
Overview
Stock analysis
Dividends
Fundamentals
BELLUS Health Inc.
0A4U
-
LSE
Overview
Stock analysis
Dividends
Fundamentals

Stock overview

Save to watchlist
0A4U
Symbol
LSE
Exchange

About stock

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

Address: 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7

Similar stocks

Report issue